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Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) threatens public health worldwide, and
epidemiologic data suggest that the Panton-Valentine Leukocidin (PVL) expressed by most CA-MRSA strains could
contribute to severe human infections, particularly in young and immunocompetent hosts. PVL is proposed to induce
cytolysis or apoptosis of phagocytes. However, recent comparisons of isogenic CA-MRSA strains with or without PVL have
revealed no differences in human PMN cytolytic activity. Furthermore, many of the mouse studies performed to date have
failed to demonstrate a virulence role for PVL, thereby provoking the question: does PVL have a mechanistic role in human
infection? In this report, we evaluated the contribution of PVL to severe skin and soft tissue infection. We generated PVL
mutants in CA-MRSA strains isolated from patients with necrotizing fasciitis and used these tools to evaluate the pathogenic
role of PVL in vivo. In a model of necrotizing soft tissue infection, we found PVL caused significant damage of muscle but not
the skin. Muscle injury was linked to induction of pro-inflammatory chemokines KC, MIP-2, and RANTES, and recruitment of
neutrophils. Tissue damage was most prominent in young mice and in those strains of mice that more effectively cleared S.
aureus, and was not significant in older mice and mouse strains that had a more limited immune response to the pathogen.
PVL mediated injury could be blocked by pretreatment with anti-PVL antibodies. Our data provide new insights into CA-
MRSA pathogenesis, epidemiology and therapeutics. PVL could contribute to the increased incidence of myositis in CA-
MRSA infection, and the toxin could mediate tissue injury by mechanisms other than direct killing of phagocytes.
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Introduction
Although previously confined to hospitals and nursing homes,
methicillin-resistant Staphylococcus aureus (MRSA) has encroached
upon immunocompetent populations and poses a growing threat
to public health worldwide [1–4]. The Panton-Valentine leuko-
cidin (PVL) is a two-component (LukS-PV and LukF-PV) pore-
forming toxin secreted by most CA-MRSA strains with demon-
strated in vitro activity against human leukocytes in its purified form
[5]. The toxin is linked in multiple clinico-epidemiological studies
to unusually severe disease pathology [6–9], especially in young,
previously healthy hosts [8,9], an association that has earned PVL
the unproven and controversial reputation of being the major
virulence determinant of severe CA-MRSA infections such as
necrotizing pneumonia, myositis and necrotizing fasciitis. The
virulence of PVL has been formally studied in the laboratory using
isogenic S. aureus strains (with or without PVL) in murine models of
skin infection and necrotizing pneumonia [10–15]. However, the
published results from multiple groups have been strongly
conflicting. In one notable study, introduction of the lukSF-PV
genes into a PVL
2 S. aureus laboratory strain significantly
enhanced pathogenic potential in a mouse pneumonia model
[12]. By contrast, deletion of lukSF-PVL from the genome of two
CA-MRSA strains, MW2 (USA400) and LAC (USA300) had no
impact on virulence of the strains in murine models of skin, lung,
and bloodstream infection in several published studies [10–13,15].
These subsequent investigations dampened enthusiasm for PVL as
a major virulence determinant of CA-MRSA infections.
One caveat regarding analysis of PVL in small animal models is a
demonstrable species specificity of toxin susceptibility; for example,
human cells have been reported to be 10-fold more susceptible to
PVL-mediated lysis than mouse cells in vitro [34]. Two groups have
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6387reported that administration of microgram amounts of purified PVL
toxins under the skin of rabbits or into the lung of mice produced
significant pathology and inflammation [12,16]. The findings suggest
that PVL expression by live CA-MRSA strains during mouse or
rabbit infection could be below a critical threshold for tissue injury,
thus accounting for the lack of a consistent PVL-related pathology.
To probe this possibility, we investigated in a mouse skin and soft
tissue infection model whether administration of a higher inoculum of
CA-MRSA would uncover a PVL virulence phenotype.
Results
PVL contributes to muscle but not skin injury
Bacterial strains applied to our infection model included two
PVL
+ USA300 strains isolated from wounds of patients with
necrotizing fasciitis (CST5 and CST6), a PVL
2 strain (Newman)
and PVL
+ or PVL
2 isogenic strains engineered from these bacteria
[22] (Table S1). A Western blot confirming PVL expression by
PVL
+ strains, but not PVL
2 strains, is shown in Figure 1A.
Previous investigations have demonstrated that a minimum
inoculum of 10
7 bacteria is typically required to induce a consistent
skinlesion inmice[10], and inocula between 10
7 and 10
8 CFU have
been routinely used in S. aureus skin infection studies. To determine
whether a higher inoculum would unveil a PVL virulence role, CD1
mice were inoculated subcutaneously on one flank with 10
9 CFU of
aP V L
+ strain, and on the opposite flank with an equal inoculum of
an isogenic PVL
2 strain. The mice were euthanized on day 3 for
analysis of lesions. As shown in Figure 1A and B, mice exhibited no
differences in skin lesion size at the site infected with PVL
+ or PVL
2
strains. Unexpectedly however, PVL
+ strains induced larger muscle
lesions compared to isogenic PVL
2 strains (Figure 1A and C), and
complementation of the mutant with a PVL expression vector
restored the ability to cause more severe muscle injury (Figure S2A).
The number of bacteria recovered from lesions produced by PVL
+
and PVL
2 bacteria were comparable (Figure 1D and S2B); hence
the increased lesion severity associated with PVL
+ strains could not
be explained by increased bacterial survival in vivo. CD1 mice,
infected with 10
7 or 10
8 PVL
+ or PVL
2 isogenic strains, showed no
difference in muscle tissue injury (Figure S1).
Histology and PVL expression in infected tissue
To determine whether PVL
+ and PVL
2 strains contribute to
differences in tissue histology, H&E stain was performed. Overall,
H&E stain showed marked necrosis and neutrophil infiltration
within the central focus of infection produced by PVL
+ or PVL
2
strains, but beyond lesion size differences, a clear-cut difference in
pathology was not discernable (Figure S3).
To evaluate PVL expression in injured tissues, infected skin and
muscle were excised for PVL immunofluorescence and histologic
analyses. As evidenced by diffuse staining throughout the tissue
Figure 1. PVL promotes muscle injury. CD1 mice were injected subcutaneously with 10
9 PVL
+ S. aureus (Newman+PVL vector, CST5, CST6) on
one flank, and 10
9 isogenic PVL
2 S. aureus (Newman+empty vector, PVL
2 CST5, PVL
2 CST6) on the opposite flank. Mice were sacrificed 3 days post-
infection. For data set B–D, graphs on the left display ratios of lesion sizes or ratios of CFU (PVL
+:PVL
2) based on measurements from each individual
mouse; graphs on the right show lesion sizes or CFU grouped according to bacterial strains. (A) Left: Western blot showing expression of LukF-PV,
LukS-PV, and a-toxin by CST5+/2PVL and CST6+/2PVL; right: Representative images of skin and muscle lesions. Arrows point to muscle lesion. (B)
Skin lesion sizes (C) muscle lesion sizes. (D) Total tissue CFU. In 1C (right panel), muscle lesions harvested from the same mice are joined by a line. *
p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0006387.g001
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+ necrotizing fasciitis clinical isolate (CST5) and
PVL
+ Newman strain both expressed the toxin in vivo (Figure 2A).
PVL staining was particularly prominent around PVL
+ S. aureus
clusters, but was also noted on select muscle bundles, particularly
at early time points of infection (Figure 2A and B). Based on
measurement of PVL concentration by ELISA (Figure 2C), PVL
+
Newman secretes lower levels of PVL compared to CST5, even
though Newman showed a more prominent PVL effect on muscle
injury compared to CST5. The measured toxin level in tissues was
in the range of 10–20 ng/ml at day 3, and never significantly
exceeded those levels at earlier time points based on a time course
experiment performed using PVL
+ Newman (data not shown). Of
note, the ELISA is likely to underestimate the actual PVL
concentration in infected tissue since much of the toxin that
intercalated into host cell membranes might not be have been
adequately solubilized to permit measurement in an ELISA.
PVL-specific antibodies block PVL mediated muscle injury
To investigate whether blockade of PVL could reduce the
extent of muscle injury, mice were injected intraperitoneally with
PVL-specific antibodies or DPBS, then challenged the next day
with ,10
9 bacteria. As shown in Figure 3A and B, pretreatment
with PVL-specific antibodies significantly reduced the size of
muscle lesions induced by PVL
+ strains, but did not alter lesion
sizes caused by PVL
2 strains. Results of these experiments
corroborate the pathogenic role of PVL in severe soft tissue
infections in the mouse model, and once again indicate that
damage inflicted by PVL predominantly affects deep muscle
tissues but not superficial skin layers.
PVL contributes to inflammation
It is well established that host inflammation can have devastating
consequences during infection [23]. Because PVL cytolysis of PMN
is difficult to demonstrate in vitro or in vivousing live bacteria, we next
asked whether PVL induces inflammation during infection, by
excising lesions from infected CD1 mice and measuring expression
of select cytokines and chemokines by ELISA. As shown in
Figure 4A–C, PVL-expressing S. aureus Newman induced higher
levels of chemokines KC, MIP-2, and RANTES in the injured
tissues than its isogenic PVL- mutant; no differences in TNF-a and
IL1b induction were observed between the two strains (Figure 4D
and E). These results are consistent with report by Konig and
coworkers that sublytic PVL toxin concentration could induce
secretion of IL-8 (human equivalent of KC) by PMN [24].
Effect of host genetic background on PVL virulence
Next, to facilitate studies of immune response to PVL, we
repeated the infection experiments in C57/B6 mice, the back-
Figure 2. PVL expression in infected tissues. CD1 mice were injected subcutaneously with 10
9 PVL
+ S. aureus (Newman+PVL vector, CST5) on
one flank, and 10
9 isogenic PVL
2 S. aureus (Newman+empty vector, PVL
2 CST5) on the opposite flank. (A) PVL immunofluorescence staining of
uninfected and infection tissues at 72 h post-infection. Left panels: tissues were stained with PVL-FITC; middle panels: DNA was stained with DAPI;
right panels: PVL and DAPI stains were merged. E+D:epidermis-dermis layer, SA: S. aureus, and M:muscle. (B) PVL immunofluorescence staining of
uninfected and infection tissues. Shown are PVL-FITC, phalloidin conjugated to Texas Red, and DAPI (DNA) stainings of tissues collected at 30 minutes
post-infection. D: dermis, and M:muscle. (C) Level of tissue PVL measured by ELISA at 72 h post-infection. ** p,0.01.
doi:10.1371/journal.pone.0006387.g002
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Injection of C57/B6 mice with 10
9 WT CST5 and PVL
2CST5
mutant, unexpectedly, elicited muscle lesions of comparable size
(Figure 5C), suggesting that the mouse’s genetic background is a
further determinant of PVL-induced disease pathology. Previously,
Bubeck Wardenburg and colleagues have demonstrate that host
background differences could be a determinant of PVL virulence
[11,13]. In their study, PVL showedno virulence effect in C57BL/6
mice [11] but paradoxically attenuated pathogenicity of S. aureus in
BALB/c AnNHsd mice [13]. To further evaluate whether and how
the mouse genetic background and immune system contribute to
PVL mediated injury, we examined skin and soft tissue infection in
four different mouse strains: BALB/c, C57BL/6, SKH1, and CD1.
As shown in Figure 5C, PVL contributed to muscle lesions in CD1
andBALB/cmice,buthad no effecton lesion severityinSKH1 and
C57BL/6 mice. The presence of PVL related injury in any
particular strain of mouse correlated directly to differences in PVL-
associated chemokine secretion (Figure 5E and F). Specifically, the
CST5 PVL
+ strain elicited significantly higher levels of MIP-2 and
KC in CD1 and BALB/c mice compared with the isogenic PVL
2
strain, but this chemokine differential did not occur in SKH1 or
C57BL/6 mice. Furthermore, as measured by tissue MPO activity,
PVL induced increased neutrophil infiltration in CD1 and (to a
lesser extent) in BALB/c mice at 3 h post-infection, but not in
SKH1 and C57BL/6 mice (Figure 5G). No difference was observed
between WT S. aureus and the isogenic PVL knockout mutant when
MPO was measured at 12 h (Figure S4B). Overall, these results
suggest that PVL induction of host immune responses depends on
the genetic background of the mouse. We noted interestingly that
CD1 and BALB/c mice (+PVL phenotype) cleared WT CST5
infection much more effectively compared to SKH1 or C57BL/6
mice (no PVL phenotype), but developed significantly larger lesions
compared toSKH1 orC57BL/6mice(Figure 5A and B).A possible
interpretation of these findings could be that CD1 and BALB/c
mice detect and respond to PVL with an exaggerated pro-
inflammatory reaction and neutrophil recruitment, which achieves
more rapid bacterial clearance, but at a simultaneous cost of more
extensive collateral damage to host tissues.
Pathogenic effects of PVL in older mice
Previous epidemiologic studies have demonstrated an association
between PVL and severe infections among young and immuno-
competentindividuals[8,9].Toexaminewhetherpathogeniceffects
of PVL vary with age, 6 month-old mice were injected
subcutaneously with isogenic PVL
+/
2 CST5 strains. As shown in
Figure 6A–E, the 6 month old mice had significantly smaller muscle
lesions, reduced chemokine secretion, but had a much higher tissue
bacterial load compared to 10–12 week old mice. In older mice,
PVL had no impact on tissue injury, neutrophil recruitment, or
surviving CFU (Figure 6A, B and C), but had a small but significant
impact on chemokine secretion (Figure 6D and E). These results are
consistent with findings that older individuals have more limited
immune response to bacterial challenge [25–28], and have less
severe pathology associated with PVL [8,9].
Discussion
Multiple epidemiologic studies have provided compelling
evidence linking PVL to pathogenicity of S. aureus infections
[6,7,29–31]. Notably, an S. aureus strain responsible for an
epidemic in the 1950’s (phage type 81/80) also harbored the
LukFS-PV genes; the strain mysteriously disappeared following the
introduction of methicillin [32], but PVL resurfaced in the 1990’s
in association with severe cases of necrotizing pneumonia and
furunculosis in MSSA and CA-MRSA strains [8,33]. However
whether PVL itself is a causative factor responsible for increased
disease severity has been heatedly debated because of failure by
multiple groups to demonstrate that PVL has a virulence role [10–
15]. More specifically, in the skin infection model, Voyich et al.
and subsequently Bubeck Wardenburg et al. infected C57BL/6
and BALB/c mice with 10
7 WT or PVL KO in the S. aureus LAC
USA300 background. In both studies, the authors report either no
difference in skin lesion size (in BALB/c or C57BL/6 mice) or a
larger skin lesion (in BALB/c AnNHsd mice) inoculated with the
PVL mutant strain. The authors did not evaluate muscle lesions in
these studies. Brown and coworkers performed an infection
experiment using the same inoculum and bacterial strains, and
reported a visual difference in muscle lesion size on day 7, albeit
the lesion sizes were not quantitated [14]. Here, in a model of
severe soft tissue infection achieved using a higher S. aureus
inoculum, we show that PVL contributes significantly to severity of
muscle tissue pathology.
Whether PVL would have a more dramatic effect in human
infection will undoubtedly be a focal point of continued debate. At
issue are 1) the sensitivity of the mouse tissues to PVL compared to
human tissues and, 2) the level of PVL expressed in mouse versus
human tissues during CA-MRSA infections. Szmigielski and
Figure 3. Anti-PVL antibodies ameliorate severity of muscle
injury. CD1 mice were injected intraperitoneally with DPBS or rabbit
antisera against LukS-PV and LukF-PV. Twenty four hours post-injection,
mice were infected on opposite flanks with either PVL
+ or PVL
2
isogenic S. aureus. Shown are ratios of lesion sizes (PVL
+:PVL
2) and
muscle lesion sizes from individual mice on day 3 post-infection.
Bacterial inocula were (A) Newman+/2PVL, and (B) CST6+/2PVL. **
p,0.01.
doi:10.1371/journal.pone.0006387.g003
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to lysis compared to human phagocytes and show an approximate
ten fold difference in membrane permeability following purified
PVL toxin challenge as measured by 51-Cr release assay [34].
Additionally, we have found in our study that the concentration of
PVL measured in mouse tissue, following subcutaneously infection
with 10
9 PVL
+ CA-MRSA, is in the range of 10–20 ng/ml, which
even with an underestimate of the PVL concentration in infected
tissue for technical reasons (see Results), is still 50–100-fold lower
than PVL measured from human abscess samples (med-
ian,.1 mg/ml) [35]. The possibility of differential PVL induction
in human and mouse tissues in human and mouse response is
another potential confounding factor in extrapolating animal data
to the human condition. Ultimately, the role of PVL in human
diseases will need to be addressed by the use of humanized animals,
or possibly by the therapeutic effect of PVL-specific antibodies on
human CA-MRSA infections.
Notwithstanding the differences between human and mouse
infection, our model has features that mimic the human disease.
PVL in the mouse preferentially causes injury of the underlying
muscle following subcutaneous CA-MRSA injection, and
histologic evaluation showed moderate staining of muscle
tissues with anti-PVL antibodies. Consistent with this finding,
we have recently submitted a report of a child with myositis
caused by a PVL
+ methicillin-sensitive S. aureus strain, whose
muscle tissue stained selectively and strongly with a PVL specific
antibody. It is not known how PVL binding to muscle tissues or
PVL induced chemokinescontribute to muscle injury. However,
given the reported association of severe myositis with CA-
MRSA and PVL, the parallel findings in human and mouse
strongly suggest a causal link between PVL and human myositis
[36].
Multiple studies point to a strong association between PVL and
severe necrotizing pneumonia and furunculosis in the current CA-
MRSA epidemic [8,9]. These infections appear to target young
and healthy hosts, who appear to suffer more severe infection
compared to older or immunosuppressed individuals. Consistent
with these findings, we observed that PVL induced greater
inflammation and caused greater pathology in mice without
conferring a bacterial survival advantage. Further, a PVL effect on
tissue pathology was apparent in those mice with the most effective
immune clearance of S. aureus (10–12 week old CD1 and BALB/c
mice), but was insignificant in mice that had a more limited
response to the pathogen (C57BL/6, SKH1, and 6 month old
CD1 mice). These findings, when taken together with the cytokine
results, suggest a parallel between our model and the human
infection, and suggest two conclusions: 1) in CA-MRSA, a primary
pathogenic effect of PVL is to provoke an overly-robust
inflammation, and 2) the severity of PVL-specific pathology may
ultimately depend on the capacity of the host immune system for
mounting an aggressive neutrophil response to infection. These
results are consistent with human epidemiologic reports indicating
that younger, immunocompetent individuals infected with MRSA
are more susceptible to severe injury [8,9], and suggest that
individuals with enhanced immune response to pathogens are at
higher risk for more serious pathology.
Figure 4. Tissue chemokines and cytokines after infection with S. aureus Newman (+/2PVL). CD1 mice were infected on opposite flanks
with either Newman+empty vector or Newman+PVL expression vector. Infected tissues were harvested at the indicated time post-infection and
tissue chemokines and cytokines were measured by ELISA. (A) Tissue MIP-2, (B) RANTES,(C) KC, (E) TNF-a, and (D) IL-1-b. Controls consisted of DPBS
injected mice. * p,0.05.
doi:10.1371/journal.pone.0006387.g004
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primarily on the cytolytic properties of PVL. Lysis of human
phagocytes could be readily demonstrated using purified PVL
[34], but a study conducted using live WT and PVL knockout S.
aureus showed no lytic effect of the toxin on human neutrophils
across a range of bacterial concentrations [10]. Our study suggests
Figure 5. Effect of innate immunity and host background on PVL virulence function. Ten to twelve week old CD1, C57BL/6, BALB/c, and
SKH1 mice were infected on opposite flanks with either PVL
+ CST5 or PVL
2CST5 S. aureus. Mice were sacrificed at different time points for analyses.
(A–D) Effect of host background on muscle pathology and total tissue CFU 3 days post-infection with CST5+/2PVL. (A) and (B) Plot of muscle lesion
sizes and total tissue CFU after infection with WT CST5. (C) and (D) plots of lesion size ratios and CFU ratios (PVL
+:PVL
2) from individual mice. (E) and
(F) Effect of host background on tissue chemokine levels 8 h post-infection with CST5+/2PVL. (G) Effect of host background on tissue MPO activity
3 h post-infection with CST5+/2PVL. Controls consisted of DPBS injected mice (negative control) and LPS injected mice (positive control). * p,0.05,
** p,0.01, *** p,0.005, **** p,0.001.
doi:10.1371/journal.pone.0006387.g005
PVL Promotes Myositis
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doses is its ability to provoke inflammation and recruit immune
effector cells such as neutrophils through activation of inflamma-
tory molecules (e.g., RANTES, KC, and MIP-2). In vitro, PVL
induction of IL8 could be demonstrated using human neutrophils
at a concentration lower than that required to induce cell lysis
[37]. These findings suggest that PVL induced PMN cytolysis as
the primary explanation of PVL injury may need to be
reevaluated. Under our model, enhanced inflammation, particu-
larly recruitment of phagocytes, could explain PVL-associated
‘‘spider bite’’ lesions and abscesses (representing phagocyte
accumulation), which have become the most common presenta-
tion of CA-MRSA skin and soft tissue infections [38]. Though our
study highlighted differences in chemokine induction by PVL
+ and
PVL
2 strains, PVL likely induces additional pro-inflammatory
factors during infection. In tissue culture, Konig and coworkers
have shown that PVL triggers secretion of leukotriene B4 and
oxygen metabolites when incubated in the presence of human
neutrophils [37]. Hence, inflammation initiated by multiple pro-
inflammatory mediators is likely an important contributor to PVL-
mediated pathology in our model.
Finally, our data suggest that application of antibodies against
PVL could limit or even abrogate PVL-mediated injury. However,
anti-PVL antibodies may not be effective for all CA-MRSA
infections. In preliminary experiments, we have tested few
additional CA-MRSA WT and PVL KO strains (LAC and
MW2), but found that under our experimental conditions, PVL
expressed by LAC and MW2 was associated with increased
bacterial survival but similar level of muscle tissue injury on day 3
(unpublished data). We are performing more exhaustive studies in
mice to identify conditions under which PVL expressed in other S.
aureus backgrounds would induce muscle injury.
In summary, we have developed a model of severe necrotizing
soft tissue infection in which PVL shows significant contribution to
muscle injury. Though the model does not by itself resolve the
debate on the relative importance of PVL in the MRSA epidemic, it
unveils surprising parallels between the mouse and human disease,
andprovidesnovel insights towards PVL related immunopathology;
hence the model could prove to be valuable for further investigation
of PVL functions.
Materials and Methods
Bacterial strains and growth conditions
Two clinical CA-MRSA isolates (CST5 and CST6), their isogenic
PVL knockout strains, one laboratory strain (Newman) transformed
with either an empty vector or a PVL expression vector were used for
this study (Table S1). The PVL knockout of CST5 and CST6 isolates
were constructed by site-directed mutagenesis using primer pairs
GAAAGGAAATGATTTTTAGGTC, GACCTAAAAAT-
CATTTCCTTC, AATATTCTATTGGAAAGGCCACC and
CTCAATATTGTTATCAGCTTTAG to introduce two stop
codons in the lukS-PV open reading frame (ORF). The DNA
fragments containing the two stop codons were cloned into pMAD
[17], and then electroporated into RN4220. The mutant allele was
transduced into CST5 and CST6 using phage 80a using a previously
established protocol [18]. For complementation and overexpression
studies, the PVL locus was amplified by PCR
using primer pair CTGACCGCGGTATGACGGCGCATATT-
GTATCAATG, and GCCAGGATCCCACGTCAATTAA-
Figure 6. Effect of innate immunity and mouse age on PVL virulence function. Ten to twelve week old CD1 mice were infected on opposite
flanks with either PVL
+ CST5 or isogenic PVL
2 CST5. (A) Muscle lesions, (B) total tissue CFU 3 days post-infection, (C) tissue MPO activity at 3 h post-
infection, and (D) and (E) KC and MIP-2 levels at 3 h post-infection. * p,0.05, ** p,0.01, *** p,0.005.
doi:10.1371/journal.pone.0006387.g006
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aureus strains were routinely cultured on sheep blood agar plates and
colonies with comparable hemolysis phenotypes were selected for
each experiment. Bacteria were also cultured in Todd-Hewitt broth
or L- broth at 37uC with shaking at 250 rpm.
Cloning and expression of rLukF-PV and rLukS-PV
lukS-PV and lukF-PV were amplified by PCR using flanking
primer sequences (lukS-PV: CACCGAATCTAAAGCTGATAA-
CAAT and TCAATTATGTCCTTTCACTTTAATTTC; lukF-
PV CACCGCTCAACATATCACACCTGT and TTAGCTCA-
TAGGATTTTTTTCCTTAG) and cloned into pET151/
TOPO-D (Invitrogen). Recombinant PVL proteins were ex-
pressed in E. coli at 30uC in the presence of 1 mM IPTG, His6-
tagged proteins were purified over nickel/cadmium columns, and
quantitated by BCA (Pierce). The His6-tag was removed by
AcTEV protease per manufacturer’s protocol (Invitrogen), with
cleavage confirmed by SDS-PAGE.
Generation of rabbit antisera
Rabbits were hyperimmunized with 100 mg recombinant LukS-
PV or LukF-PV protein in emulsion with Freund’s adjuvant to
generate specific, high-titer antisera to both LukS-PV and LukF-
PV. For each protein, two rabbits were immunized. After 4
immunizations (on days 0, 7, 21, and 35) specific antibody titers
increased 500,000-fold for both rabbits immunized with rLukF-PV
and .2,000,000-fold for one rabbit immunized with rLukS-PV as
measured by ELISA in which plates were coated with LukS-PV
10 mg/mL. The sera were tested against alpha-hemolysin or
gamma-hemolysin in Western blot and ELISA and did not show
cross-reactivity to either.
Murine skin infection model
Ten week old SKH1, CD1, and BALB/c mice and 6 month old
CD1 mice were purchased from Charles River Laboratories.
C57BL/6 mice were obtained from The Jackson Laboratory.
Overnightbacterialculturewas diluted1:1000inprewarmedmedia
and incubated at 37uC with shaking at 250 rpm until an A540,2.5.
Bacteria were harvested by centrifugation at 4000 rpm for 10 min
at 4uC, and then washed twice with equal volume of DPBS
(Mediatech). The bacteria were resuspended in DPBS at a
concentration of ,10
8–10
10 CFU/mL (620%), and 100 mLo f
suspension were injected subcutaneously in each flank. Injections
were performed with careful visualization of the needle to assure
that the injection is not intramuscular.
For experiments assessing the therapeutic efficacy of anti-PVL
antibodies, 1 mL of rabbit antisera against LukS-PV and LukF-
PV, or DPBS was administered intraperitoneally at 24 h prior to
infection. All animal experiments were approved by the Cedars-
Sinai Committee on the Use and Care of Animals and performed
using accepted veterinary standards.
Determination of lesion size and tissue bacterial CFU
Following euthanization, skin and muscle lesions were measured
and both tissues were excised separately and homogenized in 1 mL
of DPBS for CFU determination. The homogenized suspension was
centrifuged at 15,0006g for 10 min and supernatants were stored at
280uC for subsequent analysis by ELISA. For the skin, lesions were
defined by darkened areas of necrosis; for muscle, the lesions
consistedofraisedpale ordarkened colored lesionsoverlyingthered
colored healthy tissue. An area of hyperemia is often visualized
around the muscle lesions. Muscle lesions are further differentiated
from occasional fat tissue based on color and consistency.
Our method to measure lesion size has been previously reported
[19]. Both skin and muscle lesions were quantitated by multiplying
the length and width of the lesion. Irregularly-shaped lesions were
broken down into smaller symmetrical pieces, and each piece was
measured by the same method. Thickness and weight of muscle
lesion proved technically difficult to quantitate and was not
measured in this study.
To further evaluate this methodology, we assessed retest
reproducibility (i.e., the intra-observer coefficient of variability
[CV]), inter-observer variability, and calculated intra-class corre-
lation coefficients (ICCs) [20] in a subset of lesions (n=20; half
were PVL
+ and half were PVL
2, and lesions spanned a wide
range) using two blinded observers. We also performed lesion
measurements using an independent measurement method that
utilized computer-assisted histomorphometric assessment of lesion
area (ImageJ; open-source available from the NIH at http://rsb.
info.nih.gov/ij/) [21]. Two blinded investigators with experience
in mouse anatomy and lesion measurement independently
assessed twenty lesions spanning a wide range of lesion sizes using
the manual method (i.e., measurement of lesion length and width)
and the computer-assisted histomorphometric method (i.e.,
ImageJ). Each observer then measured each lesion a second time
after the lesions were shuffled to control for order effects. Lesion
sizes were expressed as both area measurements (in mm
2) and as a
dimensionless ratio of left (i.e., PVL
+) to right (i.e., PVL
2). Intra-
observer CVs (i.e., retest reproducibility) were between 6% and
11%, inter-observer CVs were 6% to 12%. ICCs were 0.882 for
the manual method and 0.960 for the histomorphometric
technique. The overall ICC between the two methods was 0.930.
Immunofluorescent assays (IFA) and hematoxylin-eosin
(H&E) stain
For IFA, the infected tissue was excised and fixed in 10%
formalin (Medical Chemical Corporation) overnight. Paraffin
embedding and H&E staining were performed by the Department
of Pathology at Cedars-Sinai Medical Center. For IFA, tissue
sections were deparaffinized and blocked with 5% goat serum in
PBS with 0.05% Tween 20 (ISC Biosciences) (blocking buffer) for
1 hour at 37uC. After incubating samples with rabbit anti-LukS-
PV antibody (diluted at 1:200 in blocking buffer) at 37uC for
1 hour, slides were washed 5 min with PBS 3 times and incubated
with corresponding FITC-conjugated secondary antibody (Sigma).
One unit of Texas Red-phalloidin (Invitrogen) was used for
counter staining per slide. After a final wash, tissue sections were
mounted with Prolong AntiFade containing DAPI (Invitrogen). A
minimum of six mice were used for each condition. Stained slides
were examined using Olympus BX51 fluoresces microscope.
Enzyme linked immunosorbent assay (ELISA)
Mouse MIP-2, RANTES, TNF-a, IL-1b,a n dK C( R&D
Systems) specific ELISAs were performed according to the
manufacturer’s instructions. For PVL ELISA, plates were coated
o v e r n i g h ta t4 uC with known concentrations of rLukF-PV or test
samples .The wells were blocked using 5% skim milk and 0.5%
normal goat serum (Sigma) for an hour at 37uC. Rabbit anti-LukF-
PVL anti-serum (1:20,000 in the blocking buffer) was added to each
well. After 1 hour at 37uC, the wells were washed 3 times with PBS
plus 0.1% Tween-20 (wash buffer). A goat anti-rabbit IgG conjugated
to HRP (Cell Signaling) (1:5,000 in blocking buffer) was next added
for an hour at 37uC, and after 5 washes, HRP activity was detected
using TMB substrate (Fisher Scientific). Threshold detection level of
the assay is 2 ng/ml. PVL ELISA has been validated using
supernatant from mouse tissue infected with PVL
2 S. aureus,s p i k e d
with known concentrations of rLukF-PV toxin.
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Animals were euthanized at 3 and 12 h post-infection, and the
skin and muscle lesions were homogenized in 1 mL of PBS-Triton
X-100 (0.5%) with protease inhibitor cocktails (Roche). The
homogenized suspension was centrifuged at 15,0006g for 10 min
and supernatants were collected and assayed for MPO activity
according to the manufacturer’s instructions using isolated murine
polymorphonuclear cells as standard (Invitrogen).
Immunoblot analysis
Overnight bacterial cultures were standardized by %T540 to a
concentration of 10
9 CFU/mL. The supernatants were collected
by centrifugation and separated using Nu-PAGE system (Invitro-
gen). Proteins were blotted onto nitrocellulose membranes and
probed with specific antibodies against LukS-PV, LukF-PV, and a-
toxin (Sigma) and corresponding secondary antibodies conjugated
to HRP (Cell Signaling Technology Inc.). Specific proteins were
visualized using ECLplus (Amersham Biosciences).
Statistical analysis
Data were analyzed using Prism 4.03 (Graphpad Software, Inc.).
The two-tailed Wilcoxon test was used to compare paired samples.
Unpaired samples were analyzed using Mann-Whitney test. Unless
otherwise indicated, a p value less than 0.05 was considered
significant, and noted in the figures. The Kruskal-Wallis test was
used when three or more groups of data were compared. In bar
graphs, n$6 and results are presented as mean6SEM.
Supporting Information
Figure S1 Mouse infection using S. aureus inocula of 107 and
108 CFU. CD1 mice were inoculated subcutaneous on one flank
with ,107 or 108 PVL+S. aureus, and on the opposite flank with
the same inoculum of isogenic PVL- S. aureus. The injected
strains were: CST5 PVL+/2, CST6 PVL+/2, and Newma-
n+empty vector/Newman+PVL expression vector. Mice were
sacrificed on day 3 post-infection. (A) and (B) Muscle lesion size
and total CFU from mice injected with 107 CST5 PVL+/2 or
CST6 PVL+/2. (C) and (D) Muscle lesion size and total CFU
from mice injected with 108 Newman+empty vector/New-
man+PVL expression vector. * p,0.05, ** p,0.01.
Found at: doi:10.1371/journal.pone.0006387.s001 (0.08 MB TIF)
Figure S2 Complementation studies. CD1 mice were inoculated
subcutaneous on both flanks with ,109 CFU WT CST5+empty
vector, CST5 KO+empty vector, or CST5 KO+PVL expression
vector. Mice were sacrificed on day 3 post-infection. (A) Muscle
lesion size. (B) Skin lesion size. (C) Total tissue CFU. Please refer to
Table S1 for detailed description of vectors. Graphs on the left
show ratios of lesion sizes or ratios of CFU (PVL+:PVL2) based
on measurements from each individual mouse; graphs on the right
show lesion sizes or CFU grouped according to bacterial strains.
Note that there are only 6 data points showing WT/KO+PVL
ratios: Only 6 mice were injected with paired WT CST5+empty
vector on one flank and CST5 KO+PVL expression vector on the
opposite flank. ** p,0.01.
Found at: doi:10.1371/journal.pone.0006387.s002 (0.11 MB TIF)
Figure S3 H&E stain of infected tissues. CD1 mice were infected
with either PVL+ or isogenic PVL- S. aureus as previously
described. Shown are H&E stainings of uninfected and infected
tissues (at day 3 post-infection). E+D:epidermis-dermis layer, SA:
S. aureus, and M:muscle.
Found at: doi:10.1371/journal.pone.0006387.s003 (5.04 MB TIF)
Figure S4 Effect of innate immunity and host background on
PVL virulence function. Ten to twelve week old CD1, C57BL/6,
BALB/c, and SKH1 mice were infected on opposite flanks with
either PVL+CST5 or isogenic PVL- CST5. (A) Muscle lesion size
and CFU on day 3 post-infection. (B) Tissue MPO level at 3 and
12 h after subcutaneous infection of CD1 mice with CST5+/
2PVL. Controls consisted of PBS injected mice (negative control)
and LPS injected mice (positive control). * p,0.05.
Found at: doi:10.1371/journal.pone.0006387.s004 (0.07 MB TIF)
Table S1 Strains and plasmids used in this study.
Found at: doi:10.1371/journal.pone.0006387.s005 (0.06 MB
DOC)
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